Sunday 4 October 2026
Afternoon EditionRSS
ZOTPAPER

News without the noise

ZOTPAPER
Business

NeuroScientific appoints Southern Star Research to manage phase 2 Crohn's trial

Perth biotech moves closer to clinic with off-the-shelf stem cell therapy for refractory disease

By LineZotpaper
Published
Read Time2 min
Sources2 outlets
Perth-based NeuroScientific Biopharmaceuticals has appointed Australian clinical research organisation Southern Star Research to run its planned phase two clinical trial for refractory Crohn's disease, with the trial expected to start by the end of the year. The appointment is a key operational milestone for the company's patented StemSmart stem cell technology.

NeuroScientific Biopharmaceuticals has taken a significant step toward its first human trial of StemSmart, a patented stem cell therapy for refractory Crohn's disease. The company has engaged Southern Star Research, one of Australia's leading clinical research organisations (CROs), to manage the phase 2 trial in Australia and the United States.

Refractory Crohn's disease, particularly the fistulising form where ulcerations create abnormal tunnels between the bowel and other organs or skin, is notoriously difficult to treat with existing therapies. StemSmart uses mesenchymal stem cells harvested from adult donor bone marrow and processed through a patented refinement method intended to enhance their therapeutic effect.

Mesenchymal stem cells are universal donor cells, meaning no donor-recipient matching is required, positioning StemSmart as a potential off-the-shelf cell therapy administered via simple intravenous infusion.

"This appointment is a key operational milestone towards the initiation of the Phase 2 clinical trial by the end of CY2026," said NeuroScientific Biopharmaceuticals chief executive officer Nathan Smith.

Southern Star Research will identify and set up clinical sites, engage principal investigators, and coordinate logistics for delivering StemSmart to enrolled patients. The CRO was recently named best in Australia at the 2026 Asia-Pacific Bioprocessing Excellence Awards. The appointment follows the company's successful engagement with the US Food and Drug Administration.

§

Analysis

Why This Matters

  • Refractory Crohn's disease has limited treatment options; a new stem cell therapy could offer relief for patients who do not respond to standard treatments.
  • The trial represents a major step for an Australian biotech developing a novel off-the-shelf cell therapy, with potential commercial and clinical impact if successful.
  • Phase 2 results will determine whether the therapy advances to larger, pivotal trials, affecting timelines for patients and investors.

Background

Crohn's disease is a chronic inflammatory bowel condition. Refractory cases fail to respond to conventional treatments, and fistulising Crohn's is particularly severe, often requiring surgery. Cell therapies, particularly those using mesenchymal stem cells, have shown promise in modulating inflammation and repairing tissue. NeuroScientific's StemSmart is a proprietary formulation designed to improve the potency of these cells. The company has already engaged with the FDA, suggesting regulatory alignment on the trial design.

Key Perspectives

NeuroScientific Biopharmaceuticals: The company sees this appointment as a critical operational milestone, enabling it to proceed with evaluating StemSmart in patients. The off-the-shelf nature of the therapy could give it a commercial advantage if efficacy is demonstrated. Patients and clinicians: For those with refractory Crohn's, particularly fistulising disease, new therapies are urgently needed. A simple intravenous infusion without waiting for donor matching would be a major advance if proven safe and effective. Regulators (FDA and Australian authorities): The trial must meet rigorous safety and efficacy standards. Phase 2 data will inform decisions on whether the therapy warrants further study or potential accelerated approval.

What to Watch

  • Initiation of patient enrolment before the end of 2026, as targeted by the company.
  • Any updates from the FDA following the company's engagement, including potential Fast Track or Orphan Drug designations.
  • Early safety and efficacy signals from the phase 2 trial, which could affect the company's valuation and partnership opportunities.

Sources

Zotpaper

Written by software from the reporting listed above, scored by an automated standards desk, and published without a person reading it first. If something here is wrong, tell the editor and it will be put right.

How we workReport an errorSubscribe